Autonomic Nervous System Drugs — MCQs

Autonomic Nervous System Drugs Indian Medical PG Practice Questions and MCQs

Question 21: Fasciculations are caused by which of the following drugs?

A. Suxamethonium (Correct Answer)
B. Pancuronium
C. d-Tubocurarine
D. Vecuronium

Explanation: **Explanation:** The correct answer is **Suxamethonium (Succinylcholine)**. **1. Why Suxamethonium is correct:** Suxamethonium is a **depolarizing neuromuscular blocker** [1], [2]. It acts as a nicotinic acetylcholine receptor (nAChR) agonist at the motor endplate [1]. Unlike acetylcholine, it is not metabolized by acetylcholinesterase, leading to prolonged depolarization [1]. This initial stimulation causes repetitive firing of the muscle fibers, which manifests clinically as **fasciculations** (brief, spontaneous muscle contractions) before the onset of flaccid paralysis (Phase I block) [1], [2]. **2. Why the other options are incorrect:** * **Pancuronium, d-Tubocurarine, and Vecuronium:** These are **non-depolarizing neuromuscular blockers** [1], [2]. They act as competitive antagonists at the nAChR [1], [2]. By blocking the receptor without activating it, they prevent depolarization from occurring. Consequently, they cause immediate flaccid paralysis **without** preceding fasciculations. **3. NEET-PG High-Yield Clinical Pearls:** * **Metabolism:** Suxamethonium is rapidly hydrolyzed by **pseudocholinesterase** (plasma cholinesterase) [2]. Patients with a genetic deficiency of this enzyme experience prolonged apnea. * **Adverse Effects:** Fasciculations can lead to postoperative muscle pain (myalgia). Other critical side effects include **hyperkalemia** (dangerous in burn or trauma patients), increased intraocular pressure, and triggering of **malignant hyperthermia** (treated with Dantrolene). * **Phase II Block:** With prolonged infusion or high doses, suxamethonium can produce a block that resembles non-depolarizing agents (fade on Train-of-Four stimulation) [1].

Question 22: Serotonin (5-HT), released from a carcinoid tumor, mediates many of its signs and symptoms primarily through activation of the 5-HT2 receptor. Which of the following effects is most likely to result from this activation?

A. Bronchospasm (Correct Answer)
B. Constipation
C. Skeletal muscle weakness
D. Tachycardia

Explanation: **Explanation:** **1. Why Bronchospasm is Correct:** Carcinoid tumors secrete excessive amounts of Serotonin (5-HT). The **5-HT2 receptor** (specifically the 5-HT2A subtype) is coupled to the **Gq protein** pathway, which activates phospholipase C, leading to increased intracellular calcium. In smooth muscle cells, this results in contraction. When 5-HT2 receptors in the bronchial smooth muscle are activated, it leads to significant **bronchoconstriction (bronchospasm)**, a classic clinical feature of Carcinoid Syndrome. **2. Analysis of Incorrect Options:** * **B. Constipation:** Serotonin actually increases gastrointestinal motility by acting on 5-HT3 and 5-HT4 receptors. Therefore, carcinoid syndrome typically presents with **secretory diarrhea**, not constipation. * **C. Skeletal muscle weakness:** 5-HT2 receptors are primarily located on smooth muscle, platelets, and the CNS. They do not mediate neurotransmission at the neuromuscular junction; thus, they do not cause skeletal muscle weakness. * **D. Tachycardia:** While carcinoid syndrome can involve flushing and hypotension, 5-HT2 activation primarily causes vasoconstriction or vasodilation depending on the vascular bed. Tachycardia is not a direct primary effect of 5-HT2 activation; rather, bradycardia can sometimes occur via the **Bezold-Jarisch reflex** (mediated by 5-HT3 receptors). **3. NEET-PG High-Yield Pearls:** * **Carcinoid Triad:** Flushing, Diarrhea, and Bronchospasm (often with right-sided heart valvular lesions). * **Drug of Choice:** **Octreotide** (Somatostatin analog) is used to manage symptoms by inhibiting serotonin release. * **Diagnosis:** Elevated urinary **5-HIAA** (5-Hydroxyindoleacetic acid), a metabolite of serotonin. * **5-HT2 Antagonist:** **Cyproheptadine** can be used to manage the diarrhea and flushing associated with carcinoid syndrome.

Question 23: Activation of which of the following receptors causes vasoconstriction?

A. Nm receptor
B. M3 receptor
C. Nn receptor
D. ETa receptor (Correct Answer)

Explanation: **Explanation:** The correct answer is **D. ETa receptor**. **1. Why ETa receptor is correct:** Endothelin-1 (ET-1) is one of the most potent endogenous vasoconstrictors known [2]. It acts primarily through two G-protein coupled receptors: **ETa** and **ETb**. * **ETa receptors** are located on vascular smooth muscle cells [3]. Their activation leads to an increase in intracellular calcium, resulting in profound and prolonged **vasoconstriction** [1]. * (Note: ETb receptors on the endothelium actually cause vasodilation via NO release, but ETa is the dominant mediator of constriction). **2. Why the other options are incorrect:** * **Nm receptor (Option A):** These are nicotinic receptors found at the **Neuromuscular Junction**. Their activation leads to skeletal muscle contraction, not vascular smooth muscle action. * **M3 receptor (Option B):** While M3 receptors are present on vascular endothelium, their activation triggers the release of Nitric Oxide (EDRF), which leads to **vasodilation**. (In the absence of endothelium, they can cause constriction, but physiologically they are associated with dilation). * **Nn receptor (Option C):** These are nicotinic receptors found in **Autonomic Ganglia** and the adrenal medulla. While they mediate neurotransmission, they do not directly cause vasoconstriction; any vascular effect would be indirect via sympathetic ganglionic stimulation. **3. Clinical Pearls for NEET-PG:** * **Bosentan:** A dual ETa and ETb receptor antagonist used in the treatment of **Pulmonary Arterial Hypertension (PAH)** [4]. * **Ambrisentan:** A selective ETa receptor antagonist also used for PAH. * **High-Yield Constrictors:** Remember the "Big Three" for exams: **Alpha-1 (α1)**, **Angiotensin II (AT1)**, and **Endothelin (ETa)**. * **M3 Paradox:** M3 activation causes *contraction* of all smooth muscles (gut, bladder, bronchi) **EXCEPT** vascular smooth muscle, where it causes *relaxation* (via NO).

Question 24: What effect can timolol produce in an asthmatic patient?

A. Bronchodilation
B. Bronchospasm (Correct Answer)
C. Decreased bronchial secretions
D. Increased bronchial secretions

Explanation: **Explanation:** **Mechanism of Action:** Timolol is a **non-selective beta-adrenergic antagonist (beta-blocker)**. It blocks both $\beta_1$ receptors (primarily in the heart) and $\beta_2$ receptors (primarily in the bronchial smooth muscles). In the lungs, $\beta_2$ receptors are responsible for bronchodilation. When Timolol blocks these receptors, it prevents the action of endogenous catecholamines, leading to smooth muscle contraction and **bronchospasm**. This can be life-threatening in patients with pre-existing reactive airway diseases like asthma or COPD. **Analysis of Incorrect Options:** * **A. Bronchodilation:** This is mediated by $\beta_2$ *agonists* (e.g., Salbutamol). Timolol, being an antagonist, does the opposite. * **C & D. Bronchial Secretions:** While the autonomic nervous system influences secretions (muscarinic agonists increase them), the primary and most dangerous effect of non-selective beta-blockers in asthmatics is the mechanical narrowing of the airways (bronchospasm) rather than a change in secretion volume. **NEET-PG High-Yield Pearls:** * **Glaucoma Connection:** Timolol is frequently used topically as eye drops for Glaucoma. Despite topical administration, systemic absorption via the nasolacrimal duct can occur, sufficient to trigger fatal bronchospasm in asthmatics. * **Safe Alternatives:** In patients with asthma requiring a beta-blocker, **cardioselective ($\beta_1$) blockers** (e.g., Betaxolol for glaucoma; Metoprolol or Atenolol systemically) are preferred, though they should still be used with extreme caution. * **Contraindications:** Non-selective beta-blockers are absolute contraindications in patients with symptomatic asthma or severe COPD.

Question 25: Which drug acts as a short-acting anticholinesterase?

A. Edrophonium (Correct Answer)
B. Pyridostigmine
C. Glycopyrrolate
D. Neostigmine

Explanation: **Explanation:** **Edrophonium** is the correct answer because it is a quaternary ammonium compound that acts as a reversible, competitive **short-acting anticholinesterase**. It binds briefly to the anionic site of the acetylcholinesterase enzyme via ionic bonds. Its duration of action is extremely short (**5–15 minutes**), making it ideal for diagnostic purposes rather than long-term treatment. **Analysis of Options:** * **Pyridostigmine:** This is an intermediate-acting carbamate anticholinesterase. It is the drug of choice for the oral maintenance treatment of Myasthenia Gravis due to its longer duration (3–6 hours) and fewer muscarinic side effects compared to Neostigmine. * **Glycopyrrolate:** This is an **antimuscarinic (anticholinergic)** drug, not an anticholinesterase. It is used to reduce secretions and prevent bradycardia during the reversal of neuromuscular blockade. * **Neostigmine:** This is an intermediate-acting anticholinesterase (duration 0.5–2 hours). It is primarily used for the reversal of non-depolarizing muscle relaxants and the treatment of paralytic ileus. **High-Yield Clinical Pearls for NEET-PG:** * **Tensilon Test:** Edrophonium was historically used in the "Tensilon Test" to differentiate between a **Myasthenic crisis** (improvement in strength) and a **Cholinergic crisis** (worsening of strength). * **Chemistry:** Edrophonium lacks a carbamoyl group, which explains its rapid dissociation from the enzyme. * **Side Effects:** Due to its rapid increase in acetylcholine, it can cause significant bradycardia; therefore, **Atropine** should always be available as an antidote during testing.

Question 26: Which drug is useful for the diagnosis of myasthenia gravis?

A. Neostigmine
B. Physostigmine
C. Edrophonium (Correct Answer)
D. Atropine

Explanation: **Explanation:** **Correct Answer: C. Edrophonium** **Why Edrophonium is correct:** Edrophonium is a quaternary ammonium compound that acts as a very short-acting reversible acetylcholinesterase (AChE) inhibitor. When administered intravenously, it rapidly increases the concentration of acetylcholine at the neuromuscular junction. In patients with Myasthenia Gravis (MG), this leads to a dramatic, albeit brief (5–10 minutes), improvement in muscle strength [1]. This diagnostic procedure is known as the **Tensilon Test**. Its rapid onset and short duration of action make it the ideal agent for diagnostic purposes rather than long-term treatment [1]. **Why other options are incorrect:** * **Neostigmine:** While also an AChE inhibitor, it has a much longer duration of action (2–4 hours). It is primarily used for the **long-term management** of MG or the reversal of neuromuscular blockade, rather than initial diagnosis. * **Physostigmine:** This is a tertiary amine that **crosses the blood-brain barrier**. It is primarily used as an antidote for atropine poisoning (central anticholinergic syndrome) and is not used for MG diagnosis due to its significant CNS side effects. * **Atropine:** This is a muscarinic antagonist. It does not improve muscle strength in MG; however, it is often kept ready during a Tensilon test to manage potential cholinergic side effects like bradycardia or excessive salivation. **High-Yield Clinical Pearls for NEET-PG:** * **Tensilon Test:** Used to differentiate between a **Myasthenic Crisis** (improvement with edrophonium) and a **Cholinergic Crisis** (worsening with edrophonium). * **Ice Pack Test:** A non-pharmacological bedside test for MG; cold improves synaptic transmission by inhibiting AChE. * **Drug of Choice for Treatment:** Pyridostigmine (longer acting and better tolerated than Neostigmine). * **Gold Standard Diagnosis:** Detection of Anti-AChR antibodies or Single-fiber EMG.

Question 27: Which drug is used in the management of Benign Prostatic Hypertrophy?

A. Alpha-1 agonist
B. Alpha-1 antagonist (Correct Answer)
C. Alpha-2 agonist
D. Alpha-2 antagonist

Explanation: **Explanation:** **1. Why Alpha-1 Antagonists are Correct:** Benign Prostatic Hypertrophy (BPH) involves two components: a **static** component (enlarged prostate tissue) and a **dynamic** component (increased smooth muscle tone). The prostate gland and the bladder neck are rich in **Alpha-1A receptors**. When these receptors are stimulated, they cause smooth muscle contraction, narrowing the urethral lumen and obstructing urine flow. * **Mechanism:** Alpha-1 antagonists (blockers) inhibit these receptors, leading to the relaxation of the smooth muscle in the bladder neck and prostate. This reduces resistance to urine flow and provides rapid symptomatic relief from urinary hesitancy and urgency. **2. Why Other Options are Incorrect:** * **Alpha-1 Agonists:** These would cause contraction of the bladder neck and prostate smooth muscle, worsening the urinary obstruction. (e.g., Phenylephrine). * **Alpha-2 Agonists:** These primarily act on the CNS to decrease sympathetic outflow (e.g., Clonidine) and have no direct therapeutic role in relaxing prostatic smooth muscle. * **Alpha-2 Antagonists:** These (e.g., Yohimbine) increase norepinephrine release and do not target the specific receptors responsible for prostatic urethral resistance. **3. NEET-PG High-Yield Clinical Pearls:** * **Uroselective Blockers:** **Tamsulosin** and **Silodosin** are selective for Alpha-1A receptors. They provide relief with a lower risk of systemic hypotension compared to non-selective blockers. * **Non-selective Blockers:** Prazosin, Terazosin, and Doxazosin block both Alpha-1A and Alpha-1B (vascular) receptors. They are preferred if the patient has **co-existing hypertension**. * **Side Effects:** Watch for **"First-dose effect"** (orthostatic hypotension) and **"Floppy Iris Syndrome"** (important for patients undergoing cataract surgery). * **Combination Therapy:** Often used with **5-alpha reductase inhibitors** (e.g., Finasteride), which reduce the actual size of the prostate (static component).

Question 28: What is the mechanism of action of Tubocurarine?

A. Cholinesterase inhibitor
B. Causes membrane depolarization
C. Competitive antagonist of acetylcholine receptor (Correct Answer)
D. Inhibits opening of chloride channels

Explanation: **Explanation:** **Mechanism of Action:** Tubocurarine is the prototype of **Non-depolarizing Neuromuscular Blockers (NDNMBs)**. It acts as a **competitive antagonist** at the nicotinic acetylcholine receptors ($N_M$ receptors) located on the motor endplate. By binding to these receptors, it prevents acetylcholine (ACh) from binding, thereby preventing endplate potential and subsequent muscle contraction. This results in flaccid paralysis. **Analysis of Options:** * **Option A (Cholinesterase inhibitor):** These drugs (e.g., Neostigmine) *increase* ACh levels at the synapse. In fact, Neostigmine is used as an antidote to reverse the blockade caused by Tubocurarine. * **Option B (Causes membrane depolarization):** This describes **Depolarizing Blockers** like **Succinylcholine**, which act as agonists that cause persistent depolarization, leading to muscle relaxation. * **Option D (Inhibits opening of chloride channels):** This is not related to the neuromuscular junction; chloride channel modulation is typically associated with GABAergic drugs like benzodiazepines or barbiturates in the CNS. **High-Yield Clinical Pearls for NEET-PG:** * **Reversibility:** The block produced by Tubocurarine can be reversed by increasing the concentration of ACh (using Acetylcholinesterase inhibitors like Neostigmine). * **Adverse Effects:** Tubocurarine is notorious for **Histamine release**, which can lead to bronchospasm, hypotension, and flushing. * **Ganglionic Blockade:** At high doses, it can also block autonomic ganglia, contributing to hypotension. * **Order of Paralysis:** Small, rapidly moving muscles (eyes, fingers) are affected first; the diaphragm is the last to be paralyzed and the first to recover.

Question 29: Which of the following is a selective Alpha 2a agonist?

A. Tizanidine
B. Terazosin
C. Yohimbine
D. Dexmedetomidine (Correct Answer)

Explanation: **Explanation:** **Correct Answer: D. Dexmedetomidine** Alpha-2 ($\alpha_2$) receptors are divided into three subtypes: 2a, 2b, and 2c. **Dexmedetomidine** is a highly selective $\alpha_{2a}$ agonist. The $\alpha_{2a}$ subtype is primarily located in the locus coeruleus of the brainstem; its stimulation inhibits sympathetic outflow, leading to sedation, analgesia, and anxiolysis without significant respiratory depression. This makes it a preferred agent for ICU sedation and procedural anesthesia. **Analysis of Incorrect Options:** * **A. Tizanidine:** While it is an $\alpha_2$ agonist, it is used primarily as a centrally acting skeletal muscle relaxant. It lacks the high selectivity for the 2a subtype compared to dexmedetomidine and is used for managing spasticity. * **B. Terazosin:** This is a selective **$\alpha_1$ blocker** used in the treatment of Benign Prostatic Hyperplasia (BPH) and hypertension. It works by relaxing smooth muscles in the bladder neck and prostate. * **C. Yohimbine:** This is a selective **$\alpha_2$ antagonist**. It was historically used for erectile dysfunction but is now primarily used in research to study sympathetic activity. **High-Yield Clinical Pearls for NEET-PG:** * **Dexmedetomidine** is often described as producing "conscious sedation" or "cooperative sedation." * **Clonidine** is another $\alpha_2$ agonist but is less selective than dexmedetomidine (selectivity ratio $\alpha_2:\alpha_1$ is 1600:1 for Dexmedetomidine vs. 200:1 for Clonidine). * **Side Effects:** The most common side effects of $\alpha_2$ agonists are bradycardia and hypotension due to decreased central sympathetic tone. * **Apraclonidine/Brimonidine:** These are $\alpha_2$ agonists used topically in glaucoma to decrease aqueous humor production.

Question 30: Ergot alkaloids are used in all the following conditions except?

A. Migraine
B. Acromegaly
C. Hypertension (Correct Answer)
D. Parkinsonism

Explanation: **Explanation:** The correct answer is **Hypertension**. Ergot alkaloids are generally **contraindicated** in hypertension because they possess potent vasoconstrictive properties. **1. Why Hypertension is the Correct Answer:** Ergot alkaloids (like Ergotamine and Ergonovine) act as partial agonists at **alpha-adrenergic receptors**. This leads to significant peripheral vasoconstriction, which can cause or exacerbate high blood pressure. In fact, ergot toxicity (Ergotism) is characterized by severe ischemia and "St. Anthony’s Fire" due to intense vascular constriction. **2. Analysis of Incorrect Options:** * **Migraine:** Ergotamine and Dihydroergotamine (DHE) are classic treatments for acute migraine attacks. They work via 5-HT$_{1B/1D}$ receptor agonism, causing vasoconstriction of dilated cranial vessels and inhibiting neurogenic inflammation. * **Acromegaly:** Bromocriptine and Cabergoline are ergot derivatives that act as **D2 receptor agonists**. In the pituitary, they inhibit the release of Growth Hormone (GH), making them effective for acromegaly. * **Parkinsonism:** Bromocriptine is used as a dopamine agonist to compensate for the dopamine deficiency in the nigrostriatal pathway. **Clinical Pearls for NEET-PG:** * **Postpartum Hemorrhage (PPH):** Ergometrine (Methylergonovine) is a DOC for PPH because it causes tetanic uterine contractions, but it must be avoided in hypertensive pregnant patients (e.g., Preeclampsia). * **Hyperprolactinemia:** Cabergoline is the preferred ergot derivative due to its higher efficacy and better side-effect profile compared to Bromocriptine. * **Side Effects:** Watch for retroperitoneal, pleural, and cardiac valvular fibrosis with long-term use of certain ergots (e.g., Methysergide).

Practice by Chapter

Cholinergic Agonists

Practice Questions

Cholinergic Antagonists

Practice Questions

Adrenergic Agonists

Practice Questions

Adrenergic Antagonists

Practice Questions

Ganglionic Agents

Practice Questions

Neuromuscular Blocking Agents

Practice Questions

Autonomic Drugs in Ophthalmology

Practice Questions

Autonomic Drugs in Cardiovascular Disease

Practice Questions

Autonomic Drugs in Respiratory Disease

Practice Questions

Autonomic Drugs in Urological Disorders

Practice Questions

Want unlimited practice?

Get full access to all questions, explanations, and performance tracking.

Start For Free